Thought this might be of interest!
Always cheers me up thinking help is coming...
FoxFeed Blog
Parkinson’s Vaccine Safe in Phase I Trial
Posted by  Maggie McGuire, July 31, 2014
A treatment that could slow or stop Parkinson’s disease today took one step closer to pharmacy shelves. The Austrian biotech AFFiRiS AG announced positive results of its Phase I safety trial of a vaccine against alpha-synuclein.
Alpha-synuclein is the sticky protein that clumps in the cells of people with Parkinson’s, and AFFiRiS hopes to stop disease by inducing antibodies against alpha-synuclein accumulation. The Michael J. Fox Foundation funded this work with close to $2M, first with a grant for a pre-clinical study and then $1.5M in 2011 for the Phase I trial. It’s the first drug against alpha-synuclein to reach clinical testing.
“A treatment that could slow or stop Parkinson’s progression would be a game changer for the five million worldwide living with this disease and the many more who will become at risk as our population ages,” said MJFF CEO Todd Sherer, PhD. “This trial is one of the most promising efforts toward that goal.”
In two different doses the drug, called PD01A, was safe and tolerable. Half of those vaccinated showed alpha-synuclein antibodies, which is a promising but very early sign. Further trials will test PDO1A’s benefit to patients.
The next step is a boost study that will test the safety and effect of a boost vaccination (another dose). MJFF will support that trial, which will take place in Vienna, Austria and start recruiting in September.
The AFFiRiS trial is one study in the Foundation’s robust alpha-synuclein portfolio. Read more about other ways we’re targeting this protein.
Hear more about this study and watch MJFF CEO Todd Sherer, PhD, discuss the potential of an alpha-synuclein therapy at today’s AFFiRiS press conference in New York.

that would be great as i could cope living with pd  as i am  know if i new it was not going to progress hope is out there. i heard to day there funding the fight against cancer with  30 million

I wondered if research has anything to add?

This would be such a wonderful advance!


Hi goldengirl

We're just putting together a news story about these newly released results for our Website which should be ready later this week.

Keep an eye on the 'Research News' section here -

In the meantime, a Parkinson's UK funded researcher Dr Patrick Lewis, University of Reading has written this interesting blog 'First stage trial of new vaccine offers glimmer of hope to Parkinson’s sufferers' which you may find interesting -

Best wishes


The Research Team



Thanks, Research!

More info to cheer us up!

Perhaps 6 to 8 years will be too long to help us but maybe we can blag our way into the trials!



glimmer: to shine faintly.

How do I get on that trial?????????????



You have to be austrian live there and speak german!